U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H16ClNO.C4H4O4
Molecular Weight 401.84
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ASENAPINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.[H][C@]12CN(C)C[C@]1([H])C3=C(OC4=C2C=CC=C4)C=CC(Cl)=C3

InChI

InChIKey=GMDCDXMAFMEDAG-CHHFXETESA-N
InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE
Molecular Formula C17H16ClNO
Molecular Weight 285.768
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19876039 | https://www.ncbi.nlm.nih.gov/pubmed/18308814

Asenapine is an antipsychotic drug. The mechanism of action of asenapine, as with other drugs having efficacy in schizophrenia and bipolar disorder, is unknown. Asenapine exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 receptors, dopamine D2, D3, D4, and D1 receptors, α1 and α2-adrenergic receptors, and histamine H1 receptors, and moderate affinity for H2 receptors. In in vitro assays asenapine acts as an antagonist at these receptors. It has been suggested that the efficacy of asenapine in schizophrenia is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Asenapine is approved by the FDA for the acute treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder, with or without psychotic features, in adults.

CNS Activity

Originator

Approval Year

2009
359
Targets

Targets

Primary TargetPharmacologyConditionPotency
D(2) dopamine receptor
58
Target ID: P14416
Gene ID: 1813.0
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
Antagonist
2778
 1.3 nM [Ki]
Antagonist
2778
 0.06 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
SAPHRIS

Approved Use

SAPHRIS is indicated for the treatment of schizophrenia. SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder.

Launch Date

2009
Primary
Approved
8429
SAPHRIS

Approved Use

SAPHRIS is indicated for the treatment of schizophrenia. SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder. SAPHRIS is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder.

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.73 ng/mL
EXPERIMENT
https://onlinelibrary.wiley.com/doi/epdf/10.1002/gps.2737
5 mg 2 times / day multiple, sublingual
dose: 5 mg
route of administration: Sublingual
experiment type: MULTIPLE
co-administered:
ASENAPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32.1 ng × h/mL
EXPERIMENT
https://onlinelibrary.wiley.com/doi/epdf/10.1002/gps.2737
5 mg 2 times / day multiple, sublingual
dose: 5 mg
route of administration: Sublingual
experiment type: MULTIPLE
co-administered:
ASENAPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf
3.8 mg single, transdermal
dose: 3.8 mg
route of administration: Transdermal
experiment type: SINGLE
co-administered:
ASENAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf
3.8 mg single, transdermal
dose: 3.8 mg
route of administration: Transdermal
experiment type: SINGLE
co-administered:
ASENAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
unhealthy, pediatric patients
n = 99
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: pediatric patients
Population Size: 99
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
Disc. AE: Somnolence, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Somnolence (2%)
Abdominal pain (2%)
Nausea (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.12
unhealthy
n = 1953
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Population Size: 1953
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.12
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence (0.6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.12
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Disc. AE: Cerebrovascular disorder (NOS), Neuroleptic malignant syndrome...
AEs leading to
discontinuation/dose reduction:
Cerebrovascular disorder (NOS)
Neuroleptic malignant syndrome
Tardive dyskinesia
Orthostatic hypotension
Leukopenia
Neutropenia
Agranulocytosis
QT interval prolonged
Seizures
Cognitive impairment
Hyperglycemia
Diabetes mellitus
Dyslipidemia
Weight gain
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 2%
Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
unhealthy, pediatric patients
n = 99
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: pediatric patients
Population Size: 99
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
Nausea 2%
Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
unhealthy, pediatric patients
n = 99
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: pediatric patients
Population Size: 99
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
Somnolence 2%
Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
unhealthy, pediatric patients
n = 99
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: pediatric patients
Population Size: 99
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.16
Somnolence 0.6%
Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.12
unhealthy
n = 1953
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Population Size: 1953
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.12
Agranulocytosis Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Cerebrovascular disorder (NOS) Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Cognitive impairment Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Diabetes mellitus Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Dyslipidemia Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Hyperglycemia Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Leukopenia Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Neuroleptic malignant syndrome Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Neutropenia Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Orthostatic hypotension Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
QT interval prolonged Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Seizures Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Tardive dyskinesia Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Weight gain Disc. AE
10 mg 2 times / day multiple, sublingual
Recommended
Dose: 10 mg, 2 times / day
Route: sublingual
Route: multiple
Dose: 10 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Schizophrenia|Bipolar I disorder
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inducer
781

inhibitor
1587
inhibitor
1767
inhibitor
1852

substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
1478

CYP1A2
1524

CYP2C8
911

CYP2A6
707
UGT1A4
347

CYP1A2
1054

P-gp
1537
CYP1A2
701
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 minor [Ki 105 uM]
CYP2C8
965
 minor [Ki 360 uM]
CYP1A2
1692
 no
CYP2A6
739
 no
CYP3A4
1925
 no
CYP2D6
1891
 weak [Ki 0.016 uM]
weak (co-administration study)
Comment: asenapine increased exposure of paroxetine by 2x; asenapine had no effect on imipramine in separate study, so paroxetine may be an outlier
Page: 24.0
CYP1A2
1692
 yes [Ki 1.5 uM]
CYP2C19
1553
 yes [Ki 2 uM]
CYP3A4
1925
 yes [Ki 91.4 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT1A4
347
 major
no (co-administration study)
Comment: valproate has no effect on asenapine
Page: 23.0
CYP1A2
1054
 major
weak (co-administration study)
Comment: fluvoxamine increased cmax of asenapine 13%, auc 29%
Page: 23.0
P-gp
1537
 no
CYP2D6
1217
 yes
no (co-administration study)
Comment: paroxetine has no effect on asenapine
Page: 30.0
CYP3A4
1737
 yes
weak (co-administration study)
Comment: cimetidine has no effect on asenapine; carbamazepine has weak effect on asenapine
Page: 30.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P0036UH
1PlusChem LLC
1P009CPQ
1PlusChem LLC
1P00E9LQ
A2B Chem
AB48041
AChemBlock
10451
AK Scientific
X2936
AbovChem LLC
HY-11100
AbovChem LLC
HY-16567
ApexBio Technology
A3192
ApexBio Technology
A5010
AstaTech
43030
Axon MedChem
1503
BLD Pharm
BD154848
BLD Pharm
BD630244
BOC Sciences
85650-56-2
Chem Scene
CS-0009346
Chem Scene
CS-0859
Chem Scene
CS-1053
Compound Cloud
163091
Compound Cloud
6917875
Enamine
EN300-123441
Hairui
HR104226
Hairui
HR116489
Hangzhou APIChem Technology
AC-24116
Lab Network
LN01342767
Lab Seeker
SC-82643
MedChem Express
HY-10121
MedChem Express
HY-11100
MedChem Express
HY-16567
MolPort
MolPort-006-133-817
MolPort
MolPort-006-142-524
MolPort
MolPort-023-276-919
MolPort
MolPort-046-417-148
MolPort
MolPort-046-702-063
Molnova
M15492
Molnova
M16209
MuseChem
I000516
MuseChem
I002919
MuseChem
R027114
MuseChem
R027986
MuseChem
R037024
PI Chemicals
PI-37740
ShangHai Biochempartner
BCP05157
Sigma Aldrich
A-101
Sigma Aldrich
A7861
Sigma Aldrich
A7861|SIGMA
TargetMol
T1951
Tocris
3737
Toronto Research Chemicals
A788000
Toronto Research Chemicals
A788025
Toronto Research Chemicals
M225790
ZINC
ZINC000000002299
http://zinc15.docking.org/substances/ZINC000000002299
eMolecules
106929509
eMolecules
300929760
eMolecules
303168224
eMolecules
31217067
eMolecules
43473206
eNovation Chemicals
D389071
mcule
MCULE-3469383831
mcule
MCULE-4789699486
mcule
MCULE-5342667273
mcule
MCULE-7804068322
mcule
MCULE-8379278884
PubMed

PubMed

TitleDatePubMed
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
2007 Oct
Bipolar depression: trial-based insights to guide patient care.
2008
Acute and long-term treatment of mania.
2008
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
2008 Feb
Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.
2008 Jul 7
American psychiatric association.
2008 Jun
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
2008 Nov
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
2009 Dec
Asenapine versus olanzapine in acute mania: a double-blind extension study.
2009 Dec
Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions.
2009 Jan
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.
2009 Jul
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.
2009 Jun
Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain.
2009 Mar
Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain.
2009 May
Asenapine.
2009 Nov
Asenapine effects in animal models of psychosis and cognitive function.
2009 Nov
Asenapine.
2009 Sep
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
2010 Apr
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
2010 Apr
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.
2010 Dec 25
Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
2010 Feb 8
Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.
2010 Jul
Asenapine induces differential regional effects on serotonin receptor subtypes.
2010 Mar
Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.
2010 May
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
2010 Nov
A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.
2010 Nov 19
New antipsychotic drugs: how do their receptor-binding profiles compare?
2010 Sep
[The quest for the pharmacological treatment of schizophrenia: from conventional neuroleptics to atypical antipsychotics and beyond].
2010 Sep-Oct
Patents

Patents

WO2014090386A1
2
WO2014207664A2
2

Sample Use Guides

In Vivo Use Guide
SAPHRIS is a sublingual tablet. To ensure optimal absorption, patients should be instructed to place the tablet under the tongue and allow it to dissolve completely. The tablet will dissolve in saliva within seconds. SAPHRIS sublingual tablets should not be crushed, chewed, or swallowed. Patients should be instructed to not eat or drink for 10 minutes after administration. Schizophrenia Usual Dose for Acute Treatment in Adults: The recommended starting and target dose of SAPHRIS is 5 mg given twice daily. In short term controlled trials, there was no suggestion of added benefit with a 10 mg twice daily dose, but there was a clear increase in certain adverse reactions. The safety of doses above 10 mg twice daily has not been evaluated in clinical studies. Maintenance Treatment: Efficacy was demonstrated with SAPHRIS in a maintenance trial in patients with schizophrenia. The starting dose in this study was 5 mg twice daily with an increase up to 10 mg twice daily after 1 week based on tolerability. While there is no body of evidence available to answer the question of how long the schizophrenic patient should remain on SAPHRIS, patients should be periodically reassessed to determine the need for maintenance treatment. Bipolar Disorder Usual Dose for Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder in Adults: Monotherapy: The recommended starting dose of SAPHRIS, and the dose maintained by 90% of the patients studied, is 10 mg twice daily. The dose can be decreased to 5 mg twice daily if warranted by adverse effects or based on individual tolerability. In controlled monotherapy trials, the starting dose for SAPHRIS was 10 mg twice daily. On the second and subsequent days of the trials, the dose could be lowered to 5 mg twice daily, based on tolerability, but less than 10% of patients had their dose reduced. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials. Adjunctive Therapy: The recommended starting dose of SAPHRIS is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials. Maintenance Treatment: While there is no body of evidence available to answer the question of how long the bipolar patient should remain on SAPHRIS, whether used as monotherapy or as adjunctive therapy with lithium or valproate, it is generally recommended that responding patients be continued beyond the acute response. If SAPHRIS is used for extended periods in bipolar disorder, the physician should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.
Route of Administration: Oral
In Vitro Use Guide
like clozapine (100 nM), but at a considerably lower concentration (5 nM), asenapine significantly potentiated the NMDA-induced responses in the rat medial prefrontal cortex pyramidal neurons
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:53:43 GMT 2023
Edited
by admin
on Fri Dec 15 15:53:43 GMT 2023
Record UNII
CU9463U2E2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASENAPINE MALEATE
EMA EPAR   MART.   MI   ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
SAPHRIS
Brand Name English
ASENAPINE MALEATE [ORANGE BOOK]
Common Name English
SYCREST
Brand Name English
Asenapine maleate [WHO-DD]
Common Name English
ORG 5222
Code English
ASENAPINE MALEATE [MI]
Common Name English
ASENAPINE MALEATE [JAN]
Common Name English
1H-DIBENZ(2,3:6,7)OXEPINO(4,5-C)PYRROLE, 5-CHLORO-2,3,3A,12B-TETRAHYDRO-2-METHYL-, (3AR,12BR)-REL-, (2Z)-2-BUTENEDIOATE (1:1)
Common Name English
ASENAPINE MALEATE [MART.]
Common Name English
ASENAPINE MALEATE [USAN]
Common Name English
ORG-5222
Code English
ASENAPINE (AS MALEATE)
Common Name English
ASENAPINE MALEATE [EMA EPAR]
Common Name English
(3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2-butenedioate (1:1)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
EMA ASSESSMENT REPORTS SYCREST (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID301017360
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
MERCK INDEX
m2091
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT000010
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL3187365
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
SMS_ID
100000115274
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
PUBCHEM
6917875
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
NCI_THESAURUS
C79727
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
MESH
C064123
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
RXCUI
860647
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY RxNorm
CHEBI
71245
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
ECHA (EC/EINECS)
288-064-8
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
FDA UNII
CU9463U2E2
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
EVMPD
SUB30493
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
DAILYMED
CU9463U2E2
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
USAN
OO-20
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
CAS
85650-56-2
Created by admin on Fri Dec 15 15:53:43 GMT 2023 , Edited by admin on Fri Dec 15 15:53:43 GMT 2023
PRIMARY
Related Record Type Details
Structure of ASENAPINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ASENAPINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966